一种预防B群脑膜炎奈瑟菌病的新型疫苗的发现与研发。
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
作者信息
Zlotnick Gary W, Jones Thomas R, Liberator Paul, Hao Li, Harris Shannon, McNeil Lisa K, Zhu Duzhang, Perez John, Eiden Joseph, Jansen Kathrin U, Anderson Annaliesa S
机构信息
a Pfizer Vaccine Research; Pearl River, NY USA.
出版信息
Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293. Epub 2014 Nov 1.
Abstract
Vaccines have had a major impact on the reduction of many diseases globally. Vaccines targeted against invasive meningococcal disease (IMD) due to serogroups A, C, W, and Y are used to prevent these diseases. Until recently no vaccine had been identified that could confer broad protection against Neisseria meningitidis serogroup B (MnB). MnB causes IMD in the very young, adolescents and young adults and thus represents a significant unmet medical need. In this brief review, we describe the discovery and development of a vaccine that has the potential for broad protection against this devastating disease.
摘要
疫苗对全球许多疾病的减少产生了重大影响。针对A、C、W和Y血清群引起的侵袭性脑膜炎球菌病（IMD）的疫苗用于预防这些疾病。直到最近，还没有发现能对B群脑膜炎奈瑟菌（MnB）提供广泛保护的疫苗。MnB在婴幼儿、青少年和年轻人中引发IMD，因此代表了一项重大的未满足医疗需求。在这篇简短的综述中，我们描述了一种有潜力对这种毁灭性疾病提供广泛保护的疫苗的发现和研发情况。
相似文献
1
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293. Epub 2014 Nov 1.
2
Advances towards the prevention of meningococcal B disease: a multidimensional story.
J Infect. 2014 Jan;68 Suppl 1:S76-82. doi: 10.1016/j.jinf.2013.09.026. Epub 2013 Oct 16.
3
Quadrivalent meningococcal conjugate vaccines.
Vaccine. 2009 Jun 24;27 Suppl 2:B30-41. doi: 10.1016/j.vaccine.2009.05.003. Epub 2009 May 27.
4
Neisseria meningitidis serogroup B vaccine development.
Microb Pathog. 2013 Apr;57:33-40. doi: 10.1016/j.micpath.2013.02.003. Epub 2013 Feb 14.
5
Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
Hum Vaccin Immunother. 2016;12(2):451-66. doi: 10.1080/21645515.2015.1080400.
6
Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Postgrad Med. 2016 Aug;128(6):548-56. doi: 10.1080/00325481.2016.1203238. Epub 2016 Jul 7.
7
Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14.
8
Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.
Methods Mol Biol. 2016;1403:445-69. doi: 10.1007/978-1-4939-3387-7_25.
9
Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
Postgrad Med. 2020 Mar;132(2):184-191. doi: 10.1080/00325481.2019.1696582. Epub 2020 Mar 3.
10
Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.
Expert Rev Vaccines. 2015 May;14(5):713-36. doi: 10.1586/14760584.2015.1004317. Epub 2015 Jan 21.
引用本文的文献
1
Design of cross-reactive antigens with machine learning and high-throughput experimental evaluation.
Front Bioinform. 2025 Jul 16;5:1580967. doi: 10.3389/fbinf.2025.1580967. eCollection 2025.
2
Genomic surveillance of invasive Neisseria meningitidis isolates circulating in Paraguay, 2009-2021.
Int Microbiol. 2025 Jun 17. doi: 10.1007/s10123-025-00685-0.
3
Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains.
Diagn Microbiol Infect Dis. 2025 Oct;113(2):116920. doi: 10.1016/j.diagmicrobio.2025.116920. Epub 2025 May 30.
4
Lipoprotein Signal Peptide as Adjuvants: Leveraging Lipobox-Driven TLR2 Activation in Modern Vaccine Design.
Vaccines (Basel). 2025 Jan 2;13(1):36. doi: 10.3390/vaccines13010036.
5
Factor H binding protein (FHbp): An evaluation of genotypic diversity across serogroups.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2409502. doi: 10.1080/21645515.2024.2409502. Epub 2024 Oct 10.
6
Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor H.
FASEB Bioadv. 2024 Jun 27;6(8):235-248. doi: 10.1096/fba.2023-00077. eCollection 2024 Aug.
7
In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.
Front Immunol. 2023 Jun 29;14:1180833. doi: 10.3389/fimmu.2023.1180833. eCollection 2023.
8
Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2212570. doi: 10.1080/21645515.2023.2212570.
9
Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial.
Vaccine. 2022 Jun 21;40(28):3835-3842. doi: 10.1016/j.vaccine.2022.05.032. Epub 2022 May 21.
10
Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096.
Comput Struct Biotechnol J. 2022 Apr 18;20:2070-2081. doi: 10.1016/j.csbj.2022.04.011. eCollection 2022.
本文引用的文献
1
Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.
J Infect Dis. 2013 Aug 15;208(4):627-36. doi: 10.1093/infdis/jit239. Epub 2013 May 28.
2
A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.
Pediatr Infect Dis J. 2013 Oct;32(10):1096-101. doi: 10.1097/INF.0b013e31829aa63b.
3
Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.
4
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
Vaccine. 2013 Mar 15;31(12):1569-75. doi: 10.1016/j.vaccine.2013.01.021. Epub 2013 Jan 24.
5
A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
Pediatr Infect Dis J. 2013 Apr;32(4):364-71. doi: 10.1097/INF.0b013e31827b0d24.
6
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
Vaccine. 2012 Sep 21;30(43):6163-74. doi: 10.1016/j.vaccine.2012.07.065. Epub 2012 Aug 5.
7
A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.
Hum Vaccin Immunother. 2012 Jul;8(7):888-95. doi: 10.4161/hv.19983. Epub 2012 Jul 1.
8
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Pediatr Infect Dis J. 2012 Oct;31(10):1061-8. doi: 10.1097/INF.0b013e31826327e4.
9
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis. 2012 Aug;12(8):597-607. doi: 10.1016/S1473-3099(12)70087-7. Epub 2012 May 7.
10
Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
Hum Vaccin. 2011 Aug;7(8):881-2. doi: 10.4161/hv.7.8.16273. Epub 2011 Aug 1.
Zotero 插件